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Mesenchymal triple negative breast cancer (TNBC) cells are very sensitive to tumor necrosis factor-related
apoptosis inducing ligand (TRAIL) for reasons that are poorly understood. The purpose of this study was to
characterize a negative regulator of TRAIL sensitivity in TNBC cells and potentially predictive biomarkers of
TRAIL sensitivity in human TNBC. First, gp78, an ubiquitin ligase that facilitates endoplasmic reticulum-
associated protein degradation, was found to negatively regulate TRAIL-induced caspases-3/7 activity and
loss in viability independently of the unfolded protein response in the TNBC mesenchymal cell line MB231.
Second, TNBC cell lines sensitive to drozitumab, a TRAIL pathway agonist, were found to express the
mesenchymal markers vimentin and Axl. Vimentin and Axl were determined to be co-expressed in a
publically available cDNA microarray dataset and by immunohistochemistry in human TNBC. These
findings provide insight into a novel gp78-associated mechanism that governs sensitivity to TRAIL-induced
apoptosis in breast cancer cells and demonstrate that the proteins vimentin and Axl may predict sensitivity
to a TRAIL pathway agonist in TNBC and are identifiable in human TNBC, which reflects their potential
utility in identifying patients who may benefit from a TRAIL pathway agonist. Collectively, these findings
may aid in the selection of appropriate combinatorial therapies and the identification of TNBC-affected
patients for treatment with a TRAIL pathway agonist.
